Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Gross Margin · Q2 FY2026 · quarter ended Jun 2026
Gross margin at 45.3%
Gross margin was 45.3% in Q2 FY2026.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 40.4%
- Year-over-year change
- —
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.4% | — |
| FY2024 | 2024-12-31 | — | — |
Gross Margin vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 gross margin of 40.4% is the lowest of the 7 companies compared; the peer median is 96.0%.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 116.4% | +166.6 pp | +862.2 pp | |
| FY2025 | 100.0% | +0.0 pp | — | |
| LTM Mar 2026 | 99.3% | — | -0.7 pp | |
EVMNEvommune, Inc. | LTM Mar 2026 | 92.8% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | 88.2% | -7.7 pp | — |
| LTM Mar 2026 | 76.3% | +55.8 pp | +13.5 pp | |
| FY2025 | 40.4% | — | — | |
ORKAOruka Therapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | — | — | — |
ZURAZura Bio Limited | FY2025 | — | — | — |
| Peer median (excluding ATTO) | 96.0% | +27.9 pp | +13.5 pp | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 1.35M |
| Cost of Revenue | 313K | 804K |
| Gross Profit | (313K) | 546K |
| Gross Margin | — | 40.4% |
| Research & Development | 33.86M | 54.15M |
| Selling, General & Admin | 7.38M | 13.55M |
| Operating Expenses | 41.24M | 67.71M |
| Depreciation & Amortization | 313K | 804K |
| EBITDA | (41.24M) | (66.36M) |
| EBITDA Margin | — | -4915.2% |
| Operating Income | (41.55M) | (67.16M) |
| Operating Margin | — | -4974.7% |
| Interest Income | 3.44M | 6.63M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 1.75M | 6.53M |
| Income Before Tax | (39.8M) | (60.63M) |
| Pre-Tax Margin | — | -4490.9% |
| Income Tax Expense | 0 | 0 |
| Net Income | (39.8M) | (60.63M) |
| Net Margin | — | -4490.9% |
| EPS (Basic) | (1.05) | (1.42) |
| EPS (Diluted) | (1.05) | (1.42) |
| Weighted Avg Shares | 43.03M | 43.03M |
| Weighted Avg Shares (Diluted) | 43.03M | 43.03M |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.